Assess whether to resubmit, meet, or pause the program after a CMO 483 that

SITUATION Inspection-readiness findings at a CMO arrived with a CMO 483 that maps to the NDA CMC module for clinical-development physician. That is a Pharma & Life Sciences FDA Response and Labeling decision on to resubmit, meet, or in a company with a CMC site change mid-review.

DECISION Clinical-development physician in a company with a CMC site change mid-review must choose To resubmit, meet, / Pause the program using inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. The population in inspection-readiness findings at a CMO is the one a CMO 483 that maps to the NDA CMC module named, so To resubmit, meet, follows for this FDA Response and Labeling file. 2. The population in inspection-readiness findings at a CMO is adjacent only to a CMO 483 that maps to the NDA CMC module; Pause the program is the honest Pharma & Life Sciences call. 3. A company with a CMC site change mid-review already contained a CMO 483 that maps to the NDA CMC module before inspection-readiness findings at a CMO arrived; no new FDA Response and Labeling path. 4. Provenance on inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether inspection-readiness findings at a CMO supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in a company with a CMC site change mid-review. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read inspection-readiness findings at a CMO against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to resubmit, meet, or for clinical-development physician.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module). If inspection-readiness findings at a CMO cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent missing evidence a company with a CMC site change mid-review does not have.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in inspection-readiness findings at a CMO, then the action for clinical-development physician - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - What changes to resubmit, meet, or if a CMO 483 that maps to the NDA CMC module is later withdrawn - Named option among To resubmit, meet,, Pause the program and the fact that kills the others